Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling.
Abstract:e14518 Background: New developments have rejuvenated anti-CTLA-4 therapies, yet dose-dependent adverse events remain a core challenge, leaving dose-dependent clinical efficacy on the table. ADG126 is an anti-CTLA-4 fully human IgG1 SAFEbody with a masking peptide blocking the antigen binding site, designed to be preferentially activated in the tumor microenvironment (TME). Activated ADG126 binds to a unique and conserved epitope of CTLA-4, allowing for cross-species demonstration of improved therapeutic windo… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.